

| Date of last update | Regimen Name on NCCP website | Tumour Group | Regimen Number |
|---------------------|---|---------------|----------------|
| 04/01/2023 | Nivolumab 360mg and Ipilimumab 1mg/kg Therapy | Lung | 792 |
| 07/02/2023 | Vandetanib Monotherapy | Head & Neck | 242 |
| 01/03/2023 | Olaparib (Tablet) Monotherapy | Genitourinary | 588 |
| | | Gynaecology | 588 |
| 10/03/2023 | Pertuzumab Trastuzumab (Phesgo®) and vinORELbine | Breast | 798 |
| | Bevacizumab 15mg/kg, PACLitaxel 175mg/m2 and CISplatin 50mg/m2 Therapy | Gynaecology | 799 |
| | Cemiplimab Therapy | Gynaecology | 812 |
| | | Skin/Melanoma | 812 |
| 14/04/2023 | PACLitaxel/CISplatin alternating with PACLitaxel/Etoposide (TP/TE) Therapy | Gynaecology | 266 |
| | Pertuzumab/Trastuzumab (Phesgo®), PACLitaxel and CARBOplatin Therapy (TRAIN-2) | Breast | 790 |
| 17/04/2023 | Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) | Breast | 433 |
| | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) | Breast | 260 |
| | DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) | Breast | 432 |
| | Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy | Gynaecology | 811 |
| | Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy | Gynaecology | 817 |
| 26/04/2023 | CARBOplatin (AUC4-6) Monotherapy-21 days | Breast | 261 |
| | | Gynaecology | 261 |
| | | Head & Neck | 261 |
| | Pembrolizumab, CISplatin and 5-Fluorouracil Therapy | Head & Neck | 706 |
| 28/04/2023 | Niraparib Monotherapy | Gynaecology | 571 |

| | | | |
|------------|---|-----------------------|-----|
| | Daratumumab (SC), Bortezomib, Thalidomide and Dexamethasone Consolidation Therapy | Myeloma | 756 |
| | Larotrectinib Monotherapy - Adult (R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient | Tumour Agnostic | 758 |
| 01/05/2023 | (R*)-ICE ((riTUXimab*), Ifosfamide, CARBOplatin and Etoposide) Therapy - Outpatient | Lymphoma | 751 |
| 02/05/2023 | Bevacizumab 5mg/kg Monotherapy – 14 Day | Neuro-oncology | 813 |
| 11/05/2023 | PACLitaxel 80 (7 day) and Trastuzumab (21 day) Therapy | Breast | 815 |
| 15/05/2023 | CISplatin, Methotrexate and Vinblastine Therapy | Genitourinary | 337 |
| | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-14 Days Therapy | Genitourinary | 333 |
| | Methotrexate, Vinblastine, DOXOrubicin, CISplatin (MVAC) Therapy-28 Days | Genitourinary | 338 |
| | Vinorelbine and CISplatin Therapy-21 days | Lung | 339 |
| | Vinorelbine and CISplatin Therapy-28 days | Lung | 343 |
| | Lomustine and Bevacizumab 5mg/kg Therapy | Neuro-oncology | 742 |
| | Lomustine and Bevacizumab 7.5mg/kg Therapy | Neuro-oncology | 804 |
| | Lomustine 130mg/m ² Therapy | Neuro-oncology | 805 |
| | CISplatin, Lomustine and vinCRISTine (CLV) Therapy | Neuro-oncology | 806 |
| 01/06/2023 | Nivolumab 3mg Ipilimumab 1mg Therapy | Gastrointestinal | 551 |
| | | Genitourinary | 551 |
| | | Skin/Melanoma | 551 |
| | Pembrolizumab 200mg, CISplatin 80mg/m ² and 5-Fluorouracil Infusional Therapy | Gastrointestinal | 739 |
| 12/06/2023 | Bevacizumab 15mg/kg , CARBOplatin AUC5 and PACLitaxel 175mg/m ² | Gynaecology | 716 |
| 13/06/2023 | ESHAP Therapy | Lymphoma | 838 |
| 28/06/2023 | Zoledronic Acid Therapy-28 days | Breast, Genitourinary | 723 |
| | Zoledronic Acid Therapy-3 monthly | Breast, Genitourinary | 724 |
| | Zoledronic Acid Therapy-6 monthly | Breast, Genitourinary | 725 |
| | Nivolumab 240mg, CISplatin 80mg/m ² and 5-Fluorouracil Infusional Therapy | Gastrointestinal | 816 |

| | | | |
|------------|---|------------------|-----|
| | Nivolumab 480mg, CISPlatin 80mg/m2 and 5-Fluorouracil Infusional Therapy | Gastrointestinal | 832 |
| 10/07/2023 | ABVD Therapy | Lymphoma | 290 |
| 24/07/2023 | ICE (Ifosfamide, CARBOplatin and Etoposide) Therapy | Lymphoma | 842 |
| 28/07/2023 | Carboplatin AUC 5 and Pegylated Liposomal DOXOrubicin 30mg/m2 Therapy-28 day | Gynaecology | 624 |
| | Pegylated Liposomal DOXOrubicin 50mg/m2 28 days | Breast | 205 |
| | | Gynaecology | 205 |
| | | Sarcoma | 205 |
| | Pegylated Liposomal DOXOrubicin 20mg/m2 21 days | Sarcoma | 462 |
| | Bevacizumab 10mg/kg and Pegylated DOXOrubicin 40mg/m2 therapy | Gynaecology | 772 |
| 29/07/2023 | Gemtuzumab ozogamicin in combination with DAUNOrubicin and cytarabine Therapy (AML induction) | Leukaemia/BMT | 612 |
| 08/08/2023 | Decitabine Monotherapy – AML (28 day cycle) | Leukaemia/BMT | 231 |
| | 5-Fluorouracil and Folinic Acid Therapy-14 day | Gastrointestinal | 660 |
| 10/08/2023 | Bevacizamab 5mg/kg and Modified FOLFOX-6 Therapy-14 day | Gastrointestinal | 446 |
| | Bevacizumab 5mg/kg and FOLFIRI Therapy – 14 days | Gastrointestinal | 449 |
| | Bevacizumab 7.5mg/kg and Capecitabine 1250mg/m2 Therapy - 21 day | | |
| | Therapy- 21 day | Gastrointestinal | 623 |
| 15/08/2023 | Pembrolizumab and FOLFOX-6 Modified Therapy | Gastrointestinal | 839 |
| 01/09/2023 | DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days | Breast | 258 |
| | Nivolumab Monotherapy 240mg-14 day | Gastrointestinal | 483 |
| | | Genitourinary | 483 |
| | | Head & Neck | 483 |
| | | Lung | 483 |
| | | Skin/Melanoma | 483 |
| | | Lymphoma | 483 |
| | Nivolumab Monotherapy 480mg-28day | Gastrointestinal | 484 |
| | | Genitourinary | 484 |
| | | Head & Neck | 484 |
| | | Lung | 484 |

| | | |
|--|---------------|-----|
| | Skin/Melanoma | 484 |
| | Lymphoma | 484 |
| Durvalumab 10mg/kg Monotherapy-14 Day | Lung | 576 |
| Durvalumab 1500mg Monotherapy-28 Day | Lung | 655 |
| CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer | Gynaecology | 676 |
| Olaparib (Tablet) and Bevacizumab Therapy | Gynaecology | 746 |
| 06/09/2023 Talazoparib Therapy | Breast | 605 |
| 07/09/2023 Modified CyBorD/ Bortezomib, Cyclophosphamide and Dexamethasone –Weekly Therapy | Myeloma | 299 |
| 12/09/2023 Zanubrutinib Therapy | Lymphoma | 708 |
| 22/09/2023 Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day Therapy (DD AC-T) | Breast | 278 |
| Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T) | Breast | 485 |
| PACLitaxel Monotherapy 80mg/m2 Day 1, 8, 15 and 22 – 28 Day | Breast | 226 |
| | Genitourinary | 226 |
| | Gynaecology | 226 |
| | Lung | 226 |